46-60 of 775
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Project Oncology®Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Obesity and Cancer Screening: National Trends and Disparities Revealed
Clinician's RoundtableObesity and Cancer Screening: National Trends and Disparities Revealed
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's RoundtableAdvancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
- advertisement
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and HematologyAdjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and HematologyPatient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and HematologyKEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and HematologyCohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- advertisement
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and HematologyAmivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
Project Oncology®Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Project Oncology®Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
